Statement from Wondfo Biotech, following the Central Drugs Standard Control Organisation decision
May 01,2020 (Edit) Wondfo
It is with regret that we read the notice from the Central Drugs Standard Control Organisation (CDSCO) of India to cancel the import license granted to Wondfo SARS-CoV-2 Antibody Test (Lateral Flow Method).
 
Since the Indian Council of Medial Research (ICMR) issued the ‘Advisory on Rapid Antibody Blood Tests’ on April 27th, 2020, we have asked ICMR for more information to better understand the issue. We are disappointed that we have not received a response from the organization to date.
 
Our business continues with the strength, determination and collective effort the global pandemic requires.
 
Quality is always our first priority. Wondfo has been and will continue to be transparent about the measures we are taking to ensure the supply and accuracy of our tests and that our products meet the needs of countries as we collectively combat COVID-19.
 
Guangzhou Wondfo Biotech Co., Ltd.
 
May 01st, 2020